Supression of gastric cancer cell growth by targeting the β-catenin/T-cell factor pathway

Cancer

Volumn 109, Issue 2, 2007, Pages 188-197

  Dvory Sobol, Hadas ^a,b   Sagiv, Eyal ^a,b   Liberman, Eliezer ^a,b   Kazanov, Diana ^a   Arber, Nadir ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

catenin; Adenovirus; Gastric cancer; Gene therapy; T cell factor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; CASPASE 8; DOXORUBICIN; FLUOROURACIL; GENE PRODUCT; METHYLENE BLUE; P53 UPREGULATED MODULATOR OF APOPTOSIS PROTEIN; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; T CELL FACTOR RECEPTOR RESPONSIVE PROMOTER PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; ONCOPROTEIN; T CELL FACTOR PROTEIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTER; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; LETHAL GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WESTERN BLOTTING; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMID; PROMOTER REGION; STOMACH TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; FLOW CYTOMETRY; FLUOROURACIL; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HCT116 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; PACLITAXEL; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TCF TRANSCRIPTION FACTORS;

EID: 33846249951     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22416     Document Type: Article

References (45)

1. Stewart BW, Kleihues P, eds. World Cancer Report. Lyon, France: IARC Press; 2003.
2. Mareel M, Boterberg T, Noe V, et al. E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol. 1997;173:271-274.
3. Daniel JM, Reynolds AB. Tyrosine phosphorylation and cadherin/catenin function. Bioessays. 1997;19:883-891.
4. Ozawa M, Kemler R. Altered cell adhesion activity by pervanadate due to the dissociation of α-catenin from the E-cadherin-catenin complex. J Biol Chem. 1998;273:6166-6170.
5. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422-426.
6. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512.
7. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000;60:4761-4766.
8. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999;18:2883-2891.
9. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 2002;1:145-155.
10. Koh TJ, Bulitta CJ, Fleming JV et al. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest. 2000;106:533-539.
11. Mann B, Gelos M, Siedow A, et al. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603-1608.
12. Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science. 1996;272:1023-1026.
13. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997;275:1787-1790.
14. Fujie H, Moriya K, Shintani Y, et al. Frequent β-catenin aberration in human hepatocellular carcinoma. Hepatol Res. 2001;20:39-51.
15. Woo DK, Kim HS, Lee HS, et al. Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines. Int J Cancer. 2001;95:108-113.
16. Nakatsuru S, Yanagisawa A, Furukawa Y, et al. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet. 1992;1:559-563.
17. Clements WM, Wang J, Sarnaik A, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62:3503-3506.
18. Yu J, Zhang L, Hwang PM, et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7:673-682.
19. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683-694.
20. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
21. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. 2001;8:308-315.
22. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997;8:985-1001.
23. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:763-771.
24. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
25. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
26. Soh JW, Mao Y, Liu L, et al. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem. 2001;276:16406-16410.
27. Frankfurt OS, Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J Histochem Cytochem. 2001;49:369-378.
28. Lowy AM, Fenoglio-Preiser , Kim OJ, et al. Dysregulation of β-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann Surg Oncol. 2003; 10:284-290.
29. Gerdes B, Ramaswamy A, Simon B, et al. Analysis of beta-catenin gene mutations in pancreatic tumors. Digestion. 1999; 60:544-548.
30. Ikenoue T, Ijichi H, Kato N, et al. Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. Jpn J Cancer Res. 2002;93:1213-1220.
31. Caca K, Kolligs FT, Ji X, et al. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ. 1999;10:369-376.
32. Ebert MP, Yu J, Hoffmann J, et al. Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol. 2003; 21:1708-1714.
33. Dvory-Sobol H, Sagiv E, Kazanov D, et al. Targeting the active β-catenin pathway to treat cancer cells. Mol Cancer Ther. 2006;5(11). In press.
34. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004;6(Suppl 1):S164-S171.
35. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001;61:4445-4449.
36. Kwong KY, Zou Y, Day CP, et al. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene. 2002;21:8340-8346.
37. Lipinski KS, Djeha HA, Gawn J, et al. Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol Ther. 2004;10:150-161.
38. Malerba M, Nikolova D, Cornells J, Iggo R. Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. Cancer Gene Ther. 2005;13:273-280.
39. Ito H, Kanzawa T, Miyoshi T, et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther. 2005;16:685-698.
40. Wang H, Qian H, Yu J, et al. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006;5:380-385.
41. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 1996;3: 121-130.
42. Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res. 2000;60:1157-1161.
43. Dvory-Sobol H, Kazanov D, Arber N. Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway. Biomed Pharmacother. 2005;59(Suppl 2): S370-S374.
44. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14: 1837-1851.
45. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109:987-991.